EUVIMEDEUVIMED entdecken
Crossref

Clevidipine and a cost-saving initiative for titratable intravenous antihypertensive agents

Haley Pajunen, Joy Bittner, Roberta Aulie, Reid Larson

American Journal of Health-System Pharmacy · 2025

DOI: 10.1093/ajhp/zxaf074 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Health-System Pharmacy, 2025. Verfasst von Haley Pajunen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Aspirus St. Luke's Hospital, Duluth, MN, USA. Hauptthemen laut MEDLINE: Antihypertensive Agents, Hypertension, Pyridines, Cost Savings. Die Arbeit nennt 11 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

This quality improvement initiative assessed the utilization of clevidipine (Cleviprex) in an institutional setting. The purpose was to identify cost-saving opportunities and implement strategies to promote cost-effective and clinically appropriate use of antihypertensive agents in various clinical scenarios. Summary This research was a single-center retrospective chart review of patients who received clevidipine from January 1 to August 31, 2023. Patients who were 18 years of age or older and had at least one documented clevidipine administration were included. In the patient population, 70% received clevidipine for a surgical hypertension indication and 30% received it for a medical hypertension indication. Only 18% of patients on clevidipine received concurrent antihypertensive agents, indicating that 82% of patients received clevidipine as first-line treatment. The results also showed significant medication waste when stocking 100-mL vials of clevidipine: less than 5 mL total was administered for 76.9% of the vials used in the operating room. In a cost comparison of the institution’s titratable intravenous antihypertensives on formulary, the clevidipine 100-mL vial was the most expensive agent. A 2-phase approach to reduce medication waste and overall medication use was implemented. During phase 1, the clevidipine inventory was converted from 100-mL to 50-mL vials to reduce the amount of wasted medication. Order set revisions were carried out in phase 2 to create a guideline-directed, tiered approach to optimize antihypertensive medication therapy.

Conclusion

A review of clevidipine utilization at the institution identified multiple strategies to reduce use, medication waste, and overall medication cost through appropriate use of intravenous antihypertensive agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antihypertensive AgentsHypertensionPyridinesCost SavingsHumansRetrospective StudiesMaleMiddle AgedFemaleAgedQuality ImprovementAdministration, IntravenousCost-Benefit AnalysisDrug CostsAdult

Stichwörter der Autor:innen

Cleviprexantihypertensiveblood pressureclevidipinecost savingshypertension

Substanzen

clevidipineAntihypertensive AgentsPyridines

Autor:innen und Institutionen

  • Department of Pharmacy, Aspirus St. Luke's Hospital, Duluth, MN, USA.

Zitieren

APA

Pajunen, H., Bittner, J., Aulie, R., & Larson, R. (2025). Clevidipine and a cost-saving initiative for titratable intravenous antihypertensive agents. American Journal of Health-System Pharmacy. https://doi.org/10.1093/ajhp/zxaf074

Vancouver

Pajunen H, Bittner J, Aulie R, Larson R. Clevidipine and a cost-saving initiative for titratable intravenous antihypertensive agents. American Journal of Health-System Pharmacy. 2025. doi:10.1093/ajhp/zxaf074

BibTeX
@article{Pajunen2025,
  author = {Pajunen, Haley and Bittner, Joy and Aulie, Roberta and Larson, Reid},
  title = {Clevidipine and a cost-saving initiative for titratable intravenous antihypertensive agents},
  journal = {American Journal of Health-System Pharmacy},
  year = {2025},
  doi = {10.1093/ajhp/zxaf074}
}
Kostenlos starten →